Breztri Aerosphere is a combination inhaler used to treat adults with chronic obstructive pulmonary disease (COPD) [1][2]. It contains three active ingredients: budesonide (an inhaled corticosteroid), glycopyrrolrolate (an anticholinergic), and formoterol fumarate (a long-acting beta2-agonist) [1][3]. This triple therapy works by reducing inflammation in the airways, relaxing airway muscles, and preventing bronchospasm [1].
What is Breztri Aerosphere approved for?
Breztri Aerosphere is indicated for the maintenance treatment of patients with COPD, including chronic bronchitis and/or emphysema, who require treatment with a combination of an inhaled corticosteroid and a long-acting bronchodilator [1]. It is not intended for the relief of acute bronchospasm or asthma [1].
How does Breztri Aerosphere work?
The inhaled corticosteroid, budesonide, helps to reduce inflammation in the lungs. Glycopyrrolrolate, an anticholinergic, blocks the action of acetylcholine, a chemical that narrows the airways, thus helping to relax and widen them. Formoterol fumarate, a long-acting beta2-agonist, also relaxes the muscles in the airways, making it easier to breathe [1].
When was Breztri Aerosphere approved?
Breztri Aerosphere received U.S. Food and Drug Administration (FDA) approval in July 2020 [2].
What are the side effects of Breztri Aerosphere?
Common side effects of Breztri Aerosphere include nasopharyngitis (common cold symptoms), pneumonia, oral candidiasis (thrush), hoarseness, and sore throat [1]. Serious side effects can include pneumonia, increased risk of fractures, glaucoma, cataracts, and thrush. Patients should be monitored for signs of pneumonia and other infections [1].
How is Breztri Aerosphere administered?
Breztri Aerosphere is administered as two inhalations twice daily, once in the morning and once in the evening, using the Aerosphere inhaler device [1]. It is important to use the inhaler as prescribed and to follow proper technique for administration [1].
Can Breztri Aerosphere be used for asthma?
No, Breztri Aerosphere is not indicated for the treatment of asthma. It is specifically approved for the maintenance treatment of COPD [1].
What are the alternatives to Breztri Aerosphere for COPD?
Other treatment options for COPD include single- and dual-combination inhalers containing inhaled corticosteroids, long-acting bronchodilators (both long-acting muscarinic antagonists and long-acting beta2-agonists), and sometimes combinations of these. The choice of therapy depends on the severity of the disease, the patient's symptoms, and individual response to treatment. Examples of other COPD medications include those containing fluticasone furoate, vilanterol, umeclidinium, and indacaterol [4].
What is the patent status of Breztri Aerosphere?
Information on the patent status and expiry dates for Breztri Aerosphere can be found on resources like DrugPatentWatch.com [5]. Patents for drugs can be complex and involve multiple patents covering the active ingredients, formulation, and methods of use.
Who manufactures Breztri Aerosphere?
Breztri Aerosphere is manufactured by AstraZeneca [1].